Citations (92)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (18)
Hirotoshi Kato, Masafumi Suzuki, Kazuo Misumi & Hitoshi Kohsaka. (2023) Macrophage activation syndrome triggered by methotrexate-related lymphoproliferative disease in a patient with rheumatoid arthritis. Immunological Medicine 46:4, pages 191-195.
Read now
Read now
Xin Gao, Xuemei He, Hiroyuki Oshima, Daisuke Miyatake, Yukio Otsuka, Kota Kato, Chunxiao Cai, Tomasz Wojtkowski, Nan Song, Yuichiro Kaneko & Aixin Shi. (2022) Pharmacokinetics and Safety of Single and Multiple Doses of Peficitinib (ASP015K) in Healthy Chinese Subjects. Drug Design, Development and Therapy 16, pages 1365-1381.
Read now
Read now
Shigeko Inokuma. (2022) Search of official nationwide database in Japan for adverse events associated with disease-modifying antirheumatic drug therapies: focus on therapies in combination with methotrexate. Expert Opinion on Drug Safety 21:4, pages 573-580.
Read now
Read now
Meng-Jie Wang, Yu-Hang Zhao, Chen Fan, Ying-Jie Wang, Xin-Qi Wang, Xiang-Jun Qiu & Rui-Le Shen. (2021) Development of an UPLC-MS/MS Method for the Quantitative Analysis of Upadacitinib in Beagle Dog Plasma and Pharmacokinetics Study. Drug Design, Development and Therapy 15, pages 4167-4175.
Read now
Read now
Kosuke Kumagai, Noriaki Okumura, Yasutaka Amano, Takafumi Yayama, Tomohiro Mimura, Tsutomu Maeda, Mitsuhiko Kubo, Kanji Mori, Richard Barrett-Jolley & Shinji Imai. (2021) Consideration of differences in drug usage between young-onset and elderly-onset rheumatoid arthritis with target of low disease activity. Modern Rheumatology 31:6, pages 1094-1099.
Read now
Read now
Satoshi Muto, Nana Minamitani, Takehisa Ogura, Arata Nakajima, Koichi Nakagawa, Toru Masaka, Sumiko Hiura, Hideki Kobayashi, Hiroyoshi Kato & Hideto Kameda. (2021) Good response to methotrexate is associated with a decrease in the gene expression of ABCG2, a drug transporter, in patients with rheumatoid arthritis. Modern Rheumatology 31:6, pages 1079-1086.
Read now
Read now
Hiroko Nagafuchi, Yutaka Goto, Shotaro Suzuki, Keiichi Sakurai, Mitsuru Imamura, Takeshi Suzuki, Yoshioki Yamasaki, Tomohiko Shibata & Kimito Kawahata. (2021) Rheumatoid arthritis relapse in patients with other iatrogenic immunodeficiency-associated lymphoproliferative disorders and its treatment. Modern Rheumatology 31:6, pages 1087-1093.
Read now
Read now
Shintaro Hirata, Hiroki Kohno, Hirofumi Watanabe, Tadahiro Tokunaga, Yusuke Yoshida, Tomohiro Sugimoto, Sho Mokuda, Keisuke Oda, Takaki Nojima & Eiji Sugiyama. (2021) Tapering and discontinuation of oral glucocorticoids without deterioration of disease status in patients with rheumatoid arthritis under a stable treatment. Modern Rheumatology 31:4, pages 803-808.
Read now
Read now
Tsutomu Takeuchi, Maureen Rischmueller, Ricardo Blanco, Ricardo M Xavier, Yukitaka Ueki, Tatsuya Atsumi, Su Chen, Alan Friedman, Aileen L Pangan, Vibeke Strand & Ronald F van Vollenhoven. (2021) Upadacitinib monotherapy versus methotrexate monotherapy in methotrexate-naïve Japanese patients with rheumatoid arthritis: a sub-analysis of the Phase 3 SELECT-EARLY study. Modern Rheumatology 31:3, pages 534-542.
Read now
Read now
Yasuo Suzuki, Tomohiro Hirose, Noriko Sugiyama, Kazuto Nomura & Eduardo Campos-Alberto. (2021) Post-marketing surveillance of high-dose methotrexate (>8 mg/week) in Japanese patients with rheumatoid arthritis: A post hoc sub-analysis of patients according to duration of prior methotrexate use. Modern Rheumatology 31:3, pages 575-586.
Read now
Read now
Kumiko Sone, Yoshihiko Usui, Keiko Fujii & Hiroshi Goto. (2021) Primary Intraocular Methotrexate-related Lymphoproliferative Disorder in a Patient with Rheumatoid Arthritis Undergoing Long-term Methotrexate Therapy. Ocular Immunology and Inflammation 29:3, pages 456-459.
Read now
Read now
Yeong Wook Song, Yong-Beom Park & Jinseok Kim. (2021) LBEC0101, an etanercept biosimilar for the treatment of rheumatoid arthritis. Expert Opinion on Biological Therapy 21:1, pages 1-8.
Read now
Read now
Keiichi Sasaki, Toshikazu Tsuji, Yasutaka Kimoto, Yuki Yanagihara, Ken Masuguchi, Ayako Chikamori, Hiroyuki Watanabe, Tesshin Murakami, Daisuke Oryoji, Masafumi Hashimoto, Takahiko Horiuchi & Nobuaki Egashira. (2021) Usefulness of daily folic acid supplementation during methotrexate treatment of Japanese patients with rheumatoid arthritis. Modern Rheumatology 31:1, pages 108-113.
Read now
Read now
Soohyun Kim, Siun Kim & Howard Lee. (2020) A critical review of the United States regulatory pathways for determining the equivalence of efficacy between CT-P13 and original infliximab (Remicade®). Drug Design, Development and Therapy 14, pages 2831-2840.
Read now
Read now
Yoshiya Tanaka & Hiroyuki Izutsu. (2020) Peficitinib for the treatment of rheumatoid arthritis: an overview from clinical trials. Expert Opinion on Pharmacotherapy 21:9, pages 1015-1025.
Read now
Read now
Yoshiya Tanaka, Tsuneyo Mimori, Hisashi Yamanaka, Naomi Sunaga, Kazuo Morita, Junko Kimura & Tsutomu Takeuchi. (2020) Effectiveness, safety, and methotrexate dose-tapering pattern over two years of treatment with adalimumab and ≥12 mg/week methotrexate for early rheumatoid arthritis: Results of the HAWK postmarketing surveillance study in Japan. Modern Rheumatology 30:3, pages 424-433.
Read now
Read now
Le Zhang, Fangfang Chen, Shikai Geng, Xiaodong Wang, Liyang Gu, Yitian Lang, Ting Li & Shuang Ye. (2020) Methotrexate (MTX) Plus Hydroxychloroquine versus MTX Plus Leflunomide in Patients with MTX-Resistant Active Rheumatoid Arthritis: A 2-Year Cohort Study in Real World. Journal of Inflammation Research 13, pages 1141-1150.
Read now
Read now
Masakazu Kondo & Hisakata Yamada. (2019) Drug survival rates of biological disease-modifying antirheumatic drugs and Janus kinase-inhibitor therapy in 801 rheumatoid arthritis patients: a 14 year-retrospective study from a rheumatology clinic in Japan. Modern Rheumatology 29:6, pages 928-935.
Read now
Read now
Articles from other publishers (74)
Kenji Takami & Shigeyoshi Tsuji. (2023) Real-world retention rates of biologics in patients with rheumatoid arthritis. Scientific Reports 13:1.
Crossref
Crossref
Satoshi Kubo, Yusuke Miyazaki, Yasuyuki Todoroki, Atsushi Nagayasu, Ryuichiro Kanda, Takafumi Aritomi, Satsuki Matsunaga, Masanobu Ueno, Ippei Miyagawa, Koshiro Sonomoto, Kentaro Hanami, Shingo Nakayamada & Yoshiya Tanaka. (2023) Generation-Dependent Retention Rates and Reasons for Discontinuation of Molecular Targeted Therapies in Patients with Rheumatoid Arthritis: From FIRST Registry. Rheumatology and Therapy 10:6, pages 1705-1723.
Crossref
Crossref
Brooke Conley, Samantha Bunzli, Jonathan Bullen, Penny O’Brien, Jennifer Persaud, Tilini Gunatillake, Mandana Nikpour, Rebecca Grainger, Cheryl Barnabe & Ivan Lin. (2023) What are the core recommendations for rheumatoid arthritis care? Systematic review of clinical practice guidelines. Clinical Rheumatology 42:9, pages 2267-2278.
Crossref
Crossref
E. L. Nasonov, V. N. Amirjanova, Y. A. Olyunin, Y. V. Muravyev, A. A. Baranov, E. V. Zonova, E. N. Otteva, A. I. Zagrebneva, D. I. Abdulganieva & P. I. Pchelnikova. (2023) The use of methotrexate in rheumatoid arthritis. Recommendations of the All-Russian public organization “Association of Rheumatologists of Russia”. Rheumatology Science and Practice 61:4, pages 435-449.
Crossref
Crossref
Masahiro Shirata, Isao Ito, Masao Tanaka, Koichi Murata, Kosaku Murakami, Hiroyuki Ikeda, Issei Oi, Nobuyoshi Hamao, Kensuke Nishioka, Yasuyuki Hayashi, Miki Nagao, Motomu Hashimoto, Hiromu Ito, Hideki Ueno, Akio Morinobu & Toyohiro Hirai. (2023) Impact of methotrexate on humoral and cellular immune responses to SARS-CoV-2 mRNA vaccine in patients with rheumatoid arthritis. Clinical and Experimental Medicine.
Crossref
Crossref
Shigeki Momohara, Kei Ikeda, Masahiro Tada, Toshiaki Miyamoto, Takanori Mito, Keita Fujimoto, Ayako Shoji, Eriko Wakita & Mitsumasa Kishimoto. (2023) Patient–Physician Communication and Perception of Treatment Goals in Rheumatoid Arthritis: An Online Survey of Patients and Physicians. Rheumatology and Therapy 10:4, pages 917-931.
Crossref
Crossref
Yasumori Sobue, Mochihito Suzuki, Yoshifumi Ohashi, Hiroshi Koshima, Nobuyuki Okui, Koji Funahashi, Hisato Ishikawa, Hidenori Inoue, Shuji Asai, Kenya Terabe, Kenji Kishimoto, Daisuke Kihira, Masataka Maeda, Ryo Sato & Shiro Imagama. (2023) Relationship between frailty and methotrexate discontinuation due to adverse events in rheumatoid arthritis patients. Clinical Rheumatology 42:8, pages 2069-2077.
Crossref
Crossref
Ting Xue, Xiaomei Kong & Liang Ma. (2023) Trends in the Epidemiology of Pneumocystis Pneumonia in Immunocompromised Patients without HIV Infection. Journal of Fungi 9:8, pages 812.
Crossref
Crossref
Yoshiya Tanaka. (2023) Subcutaneous injection of methotrexate: Advantages in the treatment of rheumatoid arthritis. Modern Rheumatology 33:4, pages 633-639.
Crossref
Crossref
Yoshiya Tanaka, Kosuke Okuda, Yohei Takeuchi, Kou Katayama, Yoichiro Haji, Yuji Yamanishi, Michael Tribanek, Cecile Guimbal-Schmolck & Tsutomu Takeuchi. (2023) Efficacy and tolerability of subcutaneously administered methotrexate including dose escalation in long-term treatment of rheumatoid arthritis in a Japanese population. Modern Rheumatology 33:4, pages 680-689.
Crossref
Crossref
Kosuke Ebina, Toru Hirano, Yuichi Maeda, Yasutaka Okita, Yuki Etani, Makoto Hirao, Wataru Yamamoto, Motomu Hashimoto, Koichi Murata, Akira Onishi, Sadao Jinno, Ryota Hara, Yonsu Son, Hideki Amuro, Takuya Kotani, Hideyuki Shiba, Masaki Katayama, Keiichi Yamamoto, Atsushi Kumanogoh, Seiji Okada & Ken Nakata. (2023) Add-on effectiveness of methotrexate or iguratimod in patients with rheumatoid arthritis exhibiting an inadequate response to Janus kinase inhibitors: The ANSWER cohort study. Modern Rheumatology 33:4, pages 690-699.
Crossref
Crossref
Yoshiya Tanaka, Tsukasa Matsubara, Tatsuya Atsumi, Koichi Amano, Naoki Ishiguro, Eiji Sugiyama, Kunihiro Yamaoka, Bernard G Combe, Alan J Kivitz, Sang-Cheol Bae, Edward C Keystone, Peter Nash, Mark Genovese, Franziska Matzkies, Beatrix Bartok, Alena Pechonkina, Akira Kondo, Lei Ye, Qi Gong, Chantal Tasset & Tsutomu Takeuchi. (2023) Safety and efficacy of filgotinib for Japanese patients with RA and inadequate response to MTX: FINCH 1 52-week results and FINCH 4 48-week results. Modern Rheumatology 33:4, pages 668-679.
Crossref
Crossref
Tatsuya Atsumi, Yoshiya Tanaka, Tsukasa Matsubara, Koichi Amano, Naoki Ishiguro, Eiji Sugiyama, Kunihiro Yamaoka, René Westhovens, Daniel W T Ching, Osvaldo Daniel Messina, Gerd R Burmester, Mark Genovese, Beatrix Bartok, Alena Pechonkina, Akira Kondo, Zhaoyu Yin, Qi Gong, Chantal Tasset & Tsutomu Takeuchi. (2023) Long-term safety and efficacy of filgotinib treatment for rheumatoid arthritis in Japanese patients naïve to MTX treatment (FINCH 3). Modern Rheumatology 33:4, pages 657-667.
Crossref
Crossref
Masataka Kuwana, Naonobu Sugiyama, Shigeki Momohara, Tatsuya Atsumi, Syuji Takei, Naoto Tamura, Masayoshi Harigai, Takao Fujii, Hiroaki Matsuno, Tsutomu Takeuchi, Kazuhiko Yamamoto, Yoshinari Takasaki, Miki Tanigawa, Yutaka Endo, Tomohiro Hirose, Yosuke Morishima, Noritoshi Yoshii, Tsuneyo Mimori & Michiaki Takagi. (2023) Six-month safety and effectiveness of tofacitinib in patients with rheumatoid arthritis in Japan: Interim analysis of post-marketing surveillance. Modern Rheumatology.
Crossref
Crossref
Hideto Kameda, Sadatomo Tasaka, Toshiya Takahashi, Katsuhisa Suzuki, Naoki Soeda & Yoshiya Tanaka. (2023) Safety and effectiveness of sarilumab in Japanese patients with rheumatoid arthritis refractory to previous treatments: An interim analysis of a post-marketing surveillance. Modern Rheumatology.
Crossref
Crossref
Daisuke Sato, Hirokazu Takami, Shunsaku Takayanagi, Kazuki Taoka, Mariko Tanaka, Reiko Matsuura, Shota Tanaka & Nobuhito Saito. (2023) Lymphoproliferative disorder during temozolomide therapy; a representative case of a formidable complication and management challenges. BMC Neurology 23:1.
Crossref
Crossref
Kenta Misaki, Naoto Tamura, Takanori Azuma, Koichiro Shinoda, Masao Tanaka, Hiroshi Fujiwara, Hideki Tsuboi, Tsuyoshi Kasama, Ryusuke Yoshimi, Tadamasa Hanyu, Yoshiaki Kusaka, Makoto Hirao, Makoto Onishi, Ayumi Uchino, Tomomasa Izumiyama, Kwang-Seok Yang, Noriyoshi Ogawa, Kiyoshi Matsui, Kazuhiro Kurasawa, Satoshi Kawaai, Hidekata Yasuoka, Noriaki Okumura, Yo Ueda, Eiichi Tanaka, Eisuke Inoue, Katsuki Tsuritani, Shigeru Matsumoto, Hisashi Yamanaka & Masayoshi Harigai. (2023)
Associations of disease duration and anti-citrullinated peptide antibody status with the effectiveness of abatacept in biologic-naïve patients with rheumatoid arthritis:
Post hoc
analysis of a multicentre, real-world observational study in Japan (ORIGAMI)
. Modern Rheumatology.
Crossref
Crossref
Noboru Kitamura, Hitomi Kobayashi, Yosuke Nagasawa, Kaita Sugiyama, Hiroshi Tsuzuki, Yutaka Tanikawa, Natsumi Ikumi, Yuito Okada, Yasuo Takahashi, Satoshi Asai, Naoto Tamura, Michihiro Ogasawara, Toshio Kawamoto, Ryohei Kuwatsuru, Hiromichi Tamaki, Genki Kidoguchi, Mutsuto Tateishi, Makiko Kimura, Yuichi Mochida, Kengo Harigane, Takayuki Shimazaki, Takao Koike, Kazuhide Tanimura, Hiroshi Kataoka, Koichi Amano, Hidekata Yasuoka & Masami Takei. (2023) Risk factors associated with relapse after methotrexate dose reduction in patients with rheumatoid arthritis receiving golimumab and methotrexate combination therapy. International Journal of Rheumatic Diseases.
Crossref
Crossref
Hideto Kameda, Keiichiro Nishida, Toshihiro Nanki, Akira Watanabe, Yukiya Oshima & Shigeki Momohara. (2023) Safety and effectiveness of certolizumab pegol in Japanese patients with rheumatoid arthritis: Results from a 24-week post-marketing surveillance study. Modern Rheumatology 33:3, pages 460-471.
Crossref
Crossref
Yuji Nozaki, Motohiro Oribe, Daisuke Tomita, Tetsu Itami, Shinya Hayashi, Toshihisa Maeda, Koji Fukuda, Ryosuke Kuroda, Keiko Funahashi, Tsukasa Matsubara, Koji Kinoshita & Itaru Matsumura. (2023) Iguratimod versus salazosulfapyridine in rheumatoid arthritis patients with an inadequate response to methotrexate: Adjusted with propensity score matching. Modern Rheumatology 33:3, pages 472-480.
Crossref
Crossref
Ayako Tominaga, Katsunori Ikari, Koichiro Yano, Eiichi Tanaka, Eisuke Inoue, Masayoshi Harigai & Ken Okazaki. (2023) Surgical intervention for patients with rheumatoid arthritis is declining except for foot and ankle surgery: A single-centre, 20-year observational cohort study. Modern Rheumatology 33:3, pages 509-516.
Crossref
Crossref
Mochihito Suzuki, Shuji Asai, Ryota Hara, Yuji Hirano, Satomi Nagamine, Tetsuya Kaneko, Hideo Sakane, Tadashi Okano, Yutaka Yoshioka, Shigeyoshi Tsuji, Hiroki Wakabayashi, Yuya Takakubo, Toki Takemoto, Takayoshi Fujibayashi, Tatsuo Watanabe, Takefumi Kato, Hajime Ishikawa, Yoshihisa Nasu, Eiji Torikai, Atsushi Kaneko, Hideki Takagi, Toshifumi Fujiwara, Daisuke Kihira, Kyosuke Hattori, Kenji Kishimoto, Yoshifumi Ohashi, Yasumori Sobue, Yutaka Yokota, Tsuyoshi Nishiume, Kenya Terabe, Nobunori Takahashi, Masayo Kojima, Shiro Imagama & Toshihisa Kojima. (2023) Choice of and response to treatment in patients with early-diagnosed rheumatoid arthritis: Real-world data from an inception cohort in Japan (NICER-J). Journal of Orthopaedic Science.
Crossref
Crossref
Hiroya Tamai, Kei Ikeda, Toshiaki Miyamoto, Hiroaki Taguchi, Chang-Fu Kuo, Kichul Shin, Shintaro Hirata, Yutaka Okano, Shinji Sato, Hidekata Yasuoka, Masataka Kuwana, Tomonori Ishii, Hideto Kameda, Toshihisa Kojima, Takehiro Taninaga, Masahiko Mori, Hideaki Miyagishi, Yasunori Sato, Wen-Chan Tsai, Tsutomu Takeuchi, Yuko Kaneko, Keisuke Izumi, Yasushi Kondo, Keiko Yoshimoto, Takahisa Gono, Sung-Hwan Park, Han Joo Baek, Yun Jong Lee, In Ah Choi, Jinhyun Kim, Ping-Ning Hsu, Chun-Ming Huan, Meng-Yu Weng, Wan-Yu Sung & Tien-Tsai Cheng. (2023) Reduced versus maximum tolerated methotrexate dose concomitant with adalimumab in patients with rheumatoid arthritis (MIRACLE): a randomised, open-label, non-inferiority trial. The Lancet Rheumatology 5:4, pages e215-e224.
Crossref
Crossref
Takanori Azuma, Kenta Misaki, Makio Kusaoi, Yoko Suzuki, Shinji Higa, Yoshitaka Kumon, Tamami Yoshitama, Taio Naniwa, Shinsuke Yamada, Tadashi Okano, Kimihiko Takeuchi, Kei Ikeda, Kenshi Higami, Masayuki Inoo, Tetsuji Sawada, Chonte Kang, Masatoshi Hayashi, Yuko Nagaya, Takafumi Hagiwara, Eisuke Shono, Shinkichi Himeno, Eiichi Tanaka, Eisuke Inoue, Yuri Yoshizawa, Michiaki Kadode, Hisashi Yamanaka & Masayoshi Harigai. (2023)
Influence of concomitant methotrexate use on the clinical effectiveness, retention, and safety of abatacept in biologic-naïve patients with rheumatoid arthritis:
Post-hoc
subgroup analysis of the ORIGAMI study
. Modern Rheumatology 33:2, pages 271-278.
Crossref
Crossref
Yusuke Kashiwado, Yasutaka Kimoto, Takuya Sawabe, Kensuke Irino, Shota Nakano, Junki Hiura, Qiaolei Wang, Shotaro Kawano, Masahiro Ayano, Hiroki Mitoma, Nobuyuki Ono, Yojiro Arinobu, Hiroaki Niiro, Taeko Hotta, Dongchon Kang, Koichi Akashi, Shiro Ohshima, Tsutomu Takeuchi & Takahiko Horiuchi. (2023) Antibody response to SARS-CoV-2 mRNA vaccines in patients with rheumatic diseases in Japan: Interim analysis of a multicentre cohort study. Modern Rheumatology 33:2, pages 367-372.
Crossref
Crossref
Yoshifumi Ohashi, Nobunori Takahashi, Yasumori Sobue, Mochihito Suzuki, Kyosuke Hattori, Kenji Kishimoto, Kenya Terabe, Shuji Asai, Toshihisa Kojima, Masayo Kojima & Shiro Imagama. (2023) Factors associated with frailty in rheumatoid arthritis patients with decreased renal function. Modern Rheumatology 33:2, pages 323-329.
Crossref
Crossref
Seiji Yokoyama, Yutaka Ishii & Junya Masuda. (2022) Persistence and Safety of Golimumab in Elderly Patients with Rheumatoid Arthritis and Renal Dysfunction in a Real-World Setting. Drugs - Real World Outcomes 10:1, pages 51-60.
Crossref
Crossref
Qiaozhi Hu, Hualing Wang & Ting Xu. (2023) Predicting Hepatotoxicity Associated with Low-Dose Methotrexate Using Machine Learning. Journal of Clinical Medicine 12:4, pages 1599.
Crossref
Crossref
Yoshiya Tanaka, Tsutomu Takeuchi, Daisuke Kato, Yuichiro Kaneko, Musashi Fukuda, Hiroyuki Izutsu, Mitsuhiro Rokuda & Désirée van der Heijde. (2023)
Post hoc
analysis of clinical characteristics of patients with radiographic progression in a Japanese phase 3 trial of peficitinib and methotrexate treatment (RAJ4)
. Modern Rheumatology 33:1, pages 73-80.
Crossref
Crossref
Naoki Ishiguro, Yoshiya Tanaka, Tsukasa Matsubara, Tatsuya Atsumi, Koichi Amano, Eiji Sugiyama, Kunihiro Yamaoka, Kevin Winthrop, Alan Kivitz, Gerd R Burmester, Jacques-Eric Gottenberg, Mark C Genovese, Franziska Matzkies, Ying Guo, Deyuan Jiang, Beatrix Bartok, Alena Pechonkina, Akira Kondo, Robin Besuyen & Tsutomu Takeuchi. (2023) Integrated safety analysis of filgotinib treatment for rheumatoid arthritis in patients from Japan over a median of 1.5 years. Modern Rheumatology 33:1, pages 64-72.
Crossref
Crossref
Tatsuya Atsumi, Eri Asakura, Michio Doi, Ruta Sawant, Isao Kawaguchi, Nobuhito Sasaki & Danny Liew. (2023) Number needed to treat and cost per responder of Janus kinase inhibitors approved for the treatment of moderate-to-severe rheumatoid arthritis in Japan. Modern Rheumatology 33:1, pages 54-63.
Crossref
Crossref
Makoto MIZUSHIMA, Yukitomo ISHI, Hiroshi IKEDA, Ikuma ECHIZENYA, Takuya OTSUKA, Tomoko MITSUHASHI, Shigeru YAMAGUCHI & Miki FUJIMURA. (2022) Successful Treatment of Intracranial Methotrexate-associated Lymphoproliferative Disorder without Epstein-Barr Virus Infection Using Rituximab, Methotrexate, Procarbazine, and Vincristine: A Case Report. NMC Case Report Journal 9:0, pages 237-242.
Crossref
Crossref
G. I. Gridneva, B. S. Belov & E. S. Aronova. (2022) Pneumocystis Pneumonia in Rheumatic Diseases: Prevention Issues. Antibiotics and Chemotherapy 67:9-10, pages 79-89.
Crossref
Crossref
Hiroko Nagafuchi, Yutaka Goto, Tomofumi Kiyokawa & Kimito Kawahata. (2022) Reasons for discontinuation of methotrexate in the treatment of rheumatoid arthritis and challenges of methotrexate resumption: a single-center, retrospective study. Egyptian Rheumatology and Rehabilitation 49:1.
Crossref
Crossref
Yoshifumi Ohashi, Nobunori Takahashi, Yasumori Sobue, Mochihito Suzuki, Kyosuke Hattori, Kenji Kishimoto, Kenya Terabe, Shuji Asai, Toshihisa Kojima, Masayo Kojima & Shiro Imagama. (2022) Disease activity at baseline is an independent predictor of frailty at one year in pre-frail patients with rheumatoid arthritis; a multicenter retrospective observational study. Journal of Orthopaedic Science.
Crossref
Crossref
Jianbin Xu, Lianbo Xiao, Jie Zhu, Qiu Qin, Yuedie Fang & Jin-an Zhang. (2022) Methotrexate use reduces mortality risk in rheumatoid arthritis: A systematic review and meta-analysis of cohort studies. Seminars in Arthritis and Rheumatism 55, pages 152031.
Crossref
Crossref
Eri Sugano, Eiichi Tanaka, Eisuke Inoue, Ryoko Sakai, Mai Abe, Kumiko Saka, Naohiro Sugitani, Moeko Ochiai, Rei Yamaguchi, Yoko Higuchi, Naoki Sugimoto, Katsunori Ikari, Ayako Nakajima, Hisashi Yamanaka & Masayoshi Harigai. (2022) Differences in patients’ population and efficacy/effectiveness of biologic disease–modifying antirheumatic drugs between randomized controlled trials and real-world settings in patients with rheumatoid arthritis – using the IORRA cohort. Modern Rheumatology 32:4, pages 675-685.
Crossref
Crossref
Takahiko Sugihara. (2022) Treatment strategies for elderly-onset rheumatoid arthritis in the new era. Modern Rheumatology 32:3, pages 493-499.
Crossref
Crossref
Yoshiya Tanaka, Tsukasa Matsubara, Koichi Hashizume, Norihito Amano & Tsutomu Takeuchi. (2022)
Efficacy and safety of abatacept in biologic-naïve patients with active rheumatoid arthritis by background methotrexate dose:
post hoc
analysis of a randomized, placebo-controlled, phase 4 study
. Modern Rheumatology 32:3, pages 500-507.
Crossref
Crossref
Min Jung Kim, Eun Hye Park, Anna Shin, You-Jung Ha, Yun Jong Lee, Eun Bong Lee, Han Joo Baek & Eun Ha Kang. (2022) Assessment on Treatments With Conventional Synthetic Disease-modifying Drugs Before Initiating Biologics in Patients With Rheumatoid Arthritis in Korea: A Population-based Study. Journal of Rheumatic Diseases 29:2, pages 79-88.
Crossref
Crossref
Shin-ichiro Ohmura, Yoichiro Homma, Takayuki Masui & Toshiaki Miyamoto. (2022) Factors Associated with <i>Pneumocystis jirovecii</i> Pneumonia in Patients with Rheumatoid Arthritis Receiving Methotrexate: A Single-center Retrospective Study. Internal Medicine 61:7, pages 997-1006.
Crossref
Crossref
Alessandro Giollo, Enrico Fuzzi & Andrea Doria. (2022) Methotrexate in early rheumatoid arthritis: Is the anchor drug still holding?. Autoimmunity Reviews 21:4, pages 103031.
Crossref
Crossref
Yoshiya Tanaka, Tsukasa Matsubara, Tatsuya Atsumi, Koichi Amano, Naoki Ishiguro, Eiji Sugiyama, Kunihiro Yamaoka, Bernard G Combe, Alan J Kivitz, Sang-Cheol Bae, Edward C Keystone, Peter Nash, Franziska Matzkies, Beatrix Bartok, Alena Pechonkina, Akira Kondo, Lei Ye, Ying Guo, Chantal Tasset, John S Sundy & Tsutomu Takeuchi. (2022) Efficacy and safety of filgotinib in combination with methotrexate in Japanese patients with active rheumatoid arthritis who have an inadequate response to methotrexate: Subpopulation analyses of 24-week data of a global phase 3 study (FINCH 1). Modern Rheumatology 32:2, pages 263-272.
Crossref
Crossref
Tatsuya Atsumi, Yoshiya Tanaka, Tsukasa Matsubara, Koichi Amano, Naoki Ishiguro, Eiji Sugiyama, Kunihiro Yamaoka, René Westhovens, Daniel W.T Ching, Osvaldo Daniel Messina, Gerd R Burmester, Beatrix Bartok, Alena Pechonkina, Akira Kondo, Zhaoyu Yin, Ying Guo, Chantal Tasset, John S Sundy & Tsutomu Takeuchi. (2022) Efficacy and safety of filgotinib alone and in combination with methotrexate in Japanese patients with active rheumatoid arthritis and limited or no prior exposure to methotrexate: Subpopulation analyses of 24-week data of a global phase 3 study (FINCH 3). Modern Rheumatology 32:2, pages 273-283.
Crossref
Crossref
Takahiko Sugihara, Yutaka Kawahito, Akio Morinobu, Yuko Kaneko, Yohei Seto, Toshihisa Kojima, Hiromu Ito, Masataka Kohno, Takeo Nakayama, Yasumori Sobue, Keiichiro Nishida, Isao Matsushita, Atsuko Murashima, Masaaki Mori, Eiichi Tanaka, Shintaro Hirata, Mitsumasa Kishimoto, Hisashi Yamanaka, Masayo Kojima & Masayoshi Harigai. (2022) Systematic review for the treatment of older rheumatoid arthritis patients informing the 2020 update of the Japan College of Rheumatology clinical practice guidelines for the management of rheumatoid arthritis. Modern Rheumatology 32:2, pages 313-322.
Crossref
Crossref
Tomona Hiyama, Yosuke Harada & Yoshiaki Kiuchi. (2022) Clinical Characteristics and Efficacy of Adalimumab and Low-Dose Methotrexate Combination Therapy in Patients With Vogt–Koyanagi–Harada Disease. Frontiers in Medicine 8.
Crossref
Crossref
Masanori Funauchi & Koji Kinoshita. (2022) Problems to Consider Before Determining the Regimen of the Treatment for Juvenile Systemic Sclerosis Treatment: A Case Report Where Tocilizumab Monotherapy Succeeded Efficiently and Safely. Clinical Medicine Insights: Arthritis and Musculoskeletal Disorders 15, pages 117954412110663.
Crossref
Crossref
Hideto Kameda, Tsutomu Takeuchi, Kunihiro Yamaoka, Motohiro Oribe, Mitsuhiro Kawano, Masayuki Yokoyama, Aileen L. Pangan, Yuko Konishi, Sebastian Meerwein & Yoshiya Tanaka. (2021) Efficacy and safety of upadacitinib over 84 weeks in Japanese patients with rheumatoid arthritis (SELECT-SUNRISE). Arthritis Research & Therapy 23:1.
Crossref
Crossref
Hideto Kameda, Ayako Hirata, Takaharu Katagiri, Yuto Takakura, Yuki Inoue, Sayaka Takenaka, Hideki Ito, Kennosuke Mizushina & Takehisa Ogura. (2021) Prediction of disease flare by biomarkers after discontinuing biologics in patients with rheumatoid arthritis achieving stringent remission. Scientific Reports 11:1.
Crossref
Crossref
Ummusen Kaya Akca, Bayram Farisogullari, Gozde Kubra Yardimci, Erdal Sag, Erdal Atalay, Muserref Kasap Cuceoglu, Ozge Basaran, Levent Kilic, Seza Ozen & Yelda Bilginer. (2021) Real-world data on MTX tolerance with regimens used in children versus adults. Clinical Rheumatology 40:12, pages 5095-5102.
Crossref
Crossref
Yosuke Harada, Tomona Hiyama & Yoshiaki Kiuchi. (2021) Methotrexate Effectively Controls Ocular Inflammation in Japanese Patients With Non-infectious Uveitis. Frontiers in Medicine 8.
Crossref
Crossref
Se Rim Choi, Jun Won Park, Eun Bong Lee & Jin Kyun Park. (2021) Initial methotrexate dosage is not associated with an increased risk of liver toxicity in patients with rheumatoid arthritis. Clinical Rheumatology 40:11, pages 4493-4500.
Crossref
Crossref
Akihiro Ohmoto & Shigeo Fuji. (2021) Clinical features and treatment strategies for post-transplant and iatrogenic immunodeficiency-associated lymphoproliferative disorders. Blood Reviews 49, pages 100807.
Crossref
Crossref
Hideaki Yamakawa, Takashi Ogura, Hideto Kameda, Tomoo Kishaba, Tae Iwasawa, Tamiko Takemura & Kazuyoshi Kuwano. (2021) Decision-Making Strategy for the Treatment of Rheumatoid Arthritis-Associated Interstitial Lung Disease (RA-ILD). Journal of Clinical Medicine 10:17, pages 3806.
Crossref
Crossref
Kunihiro Yamaoka, Yoshiya Tanaka, Hideto Kameda, Nasser Khan, Nobuhito Sasaki, Masayoshi Harigai, Yanna Song, Ying Zhang & Tsutomu Takeuchi. (2021) The Safety Profile of Upadacitinib in Patients with Rheumatoid Arthritis in Japan. Drug Safety 44:6, pages 711-722.
Crossref
Crossref
Yuji Nozaki. (2021) Iguratimod: Novel Molecular Insights and a New csDMARD for Rheumatoid Arthritis, from Japan to the World. Life 11:5, pages 457.
Crossref
Crossref
Mai Shibata, Junko Toyoshima, Yuichiro Kaneko, Kazuo Oda, Tsuyoshi Kiyota, Atsushi Kambayashi & Tetsuya Nishimura. (2020) The Bioequivalence of Two Peficitinib Formulations, and the Effect of Food on the Pharmacokinetics of Peficitinib: Two‐Way Crossover Studies of a Single Dose of 150 mg Peficitinib in Healthy Volunteers. Clinical Pharmacology in Drug Development 10:3, pages 283-290.
Crossref
Crossref
Yuyi Zhou, Chunfang Sun & Chunyan Chen. (2021) The optimal dosage of pefcitinib for the treatment of active rheumatoid arthritis. Medicine 100:7, pages e24586.
Crossref
Crossref
Tomona Hiyama, Yosuke Harada & Yoshiaki Kiuchi. (2020) Clinical characteristics and efficacy of methotrexate in Japanese patients with noninfectious scleritis. Japanese Journal of Ophthalmology 65:1, pages 97-106.
Crossref
Crossref
Hideto Kameda, Tsutomu Takeuchi, Kunihiro Yamaoka, Motohiro Oribe, Mitsuhiro Kawano, Yijie Zhou, Ahmed A Othman, Aileen L Pangan, Susumu Kitamura, Sebastian Meerwein & Yoshiya Tanaka. (2020) Efficacy and safety of upadacitinib in Japanese patients with rheumatoid arthritis (SELECT-SUNRISE): a placebo-controlled phase IIb/III study. Rheumatology 59:11, pages 3303-3313.
Crossref
Crossref
Keigo Hayashi, Ken-Ei Sada, Yosuke Asano, Sumie Hiramatsu Asano, Yuriko Yamamura, Keiji Ohashi, Michiko Morishita, Haruki Watanabe, Mariko Narazaki, Yoshinori Matsumoto & Jun Wada. (2020) Risk of higher dose methotrexate for renal impairment in patients with rheumatoid arthritis. Scientific Reports 10:1.
Crossref
Crossref
Shouhei Nagaoka, Kou Katayama, Tsuyoshi Kasama, Masao Sato, Shigeru Ohno, Yoshiharu Amasaki, Hiroshi Kataoka, Akira Furusaki, Yujiro Kon, Masahiro Okamoto, Minoru Sasano & Akira Sagawa. (2020) Weekly split‐dose regimen for oral methotrexate reduced polyglutamation in red blood cells in patients with rheumatoid arthritis compared with single‐dose regimen: Results from a multicentered randomized control trial. International Journal of Rheumatic Diseases 23:10, pages 1328-1336.
Crossref
Crossref
Mio Tsuruoka, Jun Inoue, Eiji Kakazu, Masashi Ninomiya, Tomoaki Iwata, Akitoshi Sano & Atsushi Masamune. (2020) Methotrexate-associated Lymphoproliferative Disorder in the Liver Resembling Hepatocellular Carcinoma Treated with Transarterial Chemoembolization. Internal Medicine 59:18, pages 2255-2260.
Crossref
Crossref
Emma Sullivan, Jim Kershaw, Stuart Blackburn, Puneet Mahajan & Susan H. Boklage. (2020) Biologic Disease-Modifying Antirheumatic Drug Prescription Patterns Among Rheumatologists in Europe and Japan. Rheumatology and Therapy 7:3, pages 517-535.
Crossref
Crossref
Chihiro Iwao, Kunihiko Umekita, Shunichi Miyauchi, Masatoshi Kimura, Yuki Rikitake, Koushou Iwao, Mao Rikitake, Ayako Aizawa, Takeshi Kawaguchi, Yumi Kariya, Motohiro Matsuda, Ichiro Takajo, Kazutaka Shiomi & Akihiko Okayama. (2020) Effective Treatment with Tocilizumab in a Rheumatoid Arthritis Patient Complicated with Human T-cell Leukemia Virus Type 1-associated Myelopathy. Internal Medicine 59:15, pages 1891-1897.
Crossref
Crossref
Shunsuke Mori, Nobuyuki Arima, Masahiro Ito, Yukitaka Ueki, Yasuyo Abe, Kiyoshi Aoyagi & Shigetoshi Fujiyama. (2020) Incidence, predictive factors and severity of methotrexate-related liver injury in rheumatoid arthritis: a longitudinal cohort study. Rheumatology Advances in Practice 4:2.
Crossref
Crossref
Josef S Smolen, Robert B M Landewé, Johannes W J Bijlsma, Gerd R Burmester, Maxime Dougados, Andreas Kerschbaumer, Iain B McInnes, Alexandre Sepriano, Ronald F van Vollenhoven, Maarten de Wit, Daniel Aletaha, Martin Aringer, John Askling, Alejandro Balsa, Maarten Boers, Alfons A den Broeder, Maya H Buch, Frank Buttgereit, Roberto Caporali, Mario Humberto Cardiel, Diederik De Cock, Catalin Codreanu, Maurizio Cutolo, Christopher John Edwards, Yvonne van Eijk-Hustings, Paul Emery, Axel Finckh, Laure Gossec, Jacques-Eric Gottenberg, Merete Lund Hetland, Tom W J Huizinga, Marios Koloumas, Zhanguo Li, Xavier Mariette, Ulf Müller-Ladner, Eduardo F Mysler, Jose A P da Silva, Gyula Poór, Janet E Pope, Andrea Rubbert-Roth, Adeline Ruyssen-Witrand, Kenneth G Saag, Anja Strangfeld, Tsutomu Takeuchi, Marieke Voshaar, René Westhovens & Désirée van der Heijde. (2020) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Annals of the Rheumatic Diseases 79:6, pages 685-699.
Crossref
Crossref
Akira Onishi, Shigeo Kamitsuji, Miwa Nishida, Yuko Uemura, Miho Takahashi, Toshiharu Saito, Yuichiro Yoshida, Masaki Kobayashi, Mizuho Kawate, Keisuke Nishimura, Kenta Misaki, Yumiko Nobuhara, Takashi Nakazawa, Saori Hatachi, Goh Tsuji, Akio Morinobu & Shunichi Kumagai. (2019) Genetic and clinical prediction models for the efficacy and hepatotoxicity of methotrexate in patients with rheumatoid arthritis: a multicenter cohort study. The Pharmacogenomics Journal 20:3, pages 433-442.
Crossref
Crossref
Kota Nagai, Keisuke Matsubayashi, Kazuki Ide, Kahori Seto, Yohei Kawasaki & Koji Kawakami. (2020) Factors Influencing Placebo Responses in Rheumatoid Arthritis Clinical Trials: A Meta-Analysis of Randomized, Double-Blind, Placebo-Controlled Studies. Clinical Drug Investigation 40:3, pages 197-209.
Crossref
Crossref
Sawako ShiraiwaYara Yukie KikutiJoaquim CarrerasRyujiro HaraYasuyuki AoyamaDaisuke OgiyaRikio SuzukiMasako ToyosakiKen OhmachiYoshiaki OgawaHiroshi KawadaShinji Sato, Naoya NakamuraKiyoshi Ando. (2020) Clinicopathological evaluation of methotrexate-associated lymphoproliferative disorders with special focus on Epstein-Barr virus-positive mucocutaneous lesions. Journal of Clinical and Experimental Hematopathology 60:4, pages 159-168.
Crossref
Crossref
KWANGSEOK YANG, MASAKAZU MATSUSHITA & NAOTO TAMURA. (2020) Methotrexate and Oral Antirheumatic Drugs. Juntendo Medical Journal 66:1, pages 27-33.
Crossref
Crossref
Shizuka Miyaza, Ryosuke Matsuda, Mitsutoshi Nakamura, Ichiro Nakagawa, Yasushi Motoyama & Hiroyuki Nakase. (2019) Intracranial Methotrexate-Associated Lymphoproliferative Disorder in Rheumatoid Arthritis. World Neurosurgery 130, pages 138-141.
Crossref
Crossref
Kai‐Chun Wang, Hsien‐Tzung Liao, Wei‐Sheng Chen, Chien‐Chih Lai, Chung‐Tei Chou, Ming‐Han Chen & Chang‐Youh Tsai. (2019) Real‐world effectiveness and safety of rituximab in the treatment of rheumatoid arthritis: A single‐center experience in Taiwan. International Journal of Rheumatic Diseases 22:5, pages 860-868.
Crossref
Crossref
Kota Shimada, Kyoko Yokosuka, Takahiro Nunokawa & Shoji Sugii. (2018) Differences in clinical Pneumocystis pneumonia in rheumatoid arthritis and other connective tissue diseases suggesting a rheumatoid-specific interstitial lung injury spectrum. Clinical Rheumatology 37:8, pages 2269-2274.
Crossref
Crossref